- Home
- AGI vs NBIX Comparison
AGI vs NBIX Comparison
Compare AGI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- NBIX
- Stock Information
- Founded
- AGI 2003
- NBIX 1992
- Country
- AGI Canada
- NBIX United States
- Employees
- AGI N/A
- NBIX N/A
- Industry
- AGI Precious Metals
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGI Basic Materials
- NBIX Health Care
- Exchange
- AGI Nasdaq
- NBIX Nasdaq
- Market Cap
- AGI 14.8B
- NBIX 14.4B
- IPO Year
- AGI 1999
- NBIX 1996
- Fundamental
- Price
- AGI $33.44
- NBIX $144.77
- Analyst Decision
- AGI Strong Buy
- NBIX Strong Buy
- Analyst Count
- AGI 3
- NBIX 18
- Target Price
- AGI $41.00
- NBIX $172.33
- AVG Volume (30 Days)
- AGI 4.1M
- NBIX 1.1M
- Earning Date
- AGI 10-29-2025
- NBIX 10-28-2025
- Dividend Yield
- AGI 0.30%
- NBIX N/A
- EPS Growth
- AGI 112.89
- NBIX 12.44
- EPS
- AGI 1.28
- NBIX 4.19
- Revenue
- AGI $1,609,300,000.00
- NBIX $2,682,700,000.00
- Revenue This Year
- AGI $39.28
- NBIX $23.68
- Revenue Next Year
- AGI $27.13
- NBIX $18.02
- P/E Ratio
- AGI $26.08
- NBIX $34.51
- Revenue Growth
- AGI 31.30
- NBIX 19.61
- 52 Week Low
- AGI $17.43
- NBIX $84.23
- 52 Week High
- AGI $37.54
- NBIX $157.67
- Technical
- Relative Strength Index (RSI)
- AGI 55.62
- NBIX 50.90
- Support Level
- AGI $30.21
- NBIX $145.00
- Resistance Level
- AGI $34.37
- NBIX $148.84
- Average True Range (ATR)
- AGI 1.23
- NBIX 5.31
- MACD
- AGI 0.28
- NBIX -0.33
- Stochastic Oscillator
- AGI 81.24
- NBIX 47.17
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.